These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 629275

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia.
    Embury SH, Garcia JF, Mohandas N, Pennathur-Das R, Clark MR.
    N Engl J Med; 1984 Aug 02; 311(5):291-5. PubMed ID: 6738642
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. In vitro interactions of 51Cr in human red blood cells and hemolysates.
    Kuehl GV, Harkness DR, Skrabut EM, Bechthold DA, Emerson CP, Valeri CR.
    Vox Sang; 1981 Apr 02; 40(4):260-72. PubMed ID: 7257239
    [Abstract] [Full Text] [Related]

  • 30. Drugs for preventing red blood cell dehydration in people with sickle cell disease.
    Nagalla S, Ballas SK.
    Cochrane Database Syst Rev; 2010 Jan 20; (1):CD003426. PubMed ID: 20091545
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of the in vitro formation of dense cells and of irreversibly sickled cells by charybdotoxin, a specific inhibitor of calcium-activated potassium efflux.
    Ohnishi ST, Katagi H, Katagi C.
    Biochim Biophys Acta; 1989 Feb 09; 1010(2):199-203. PubMed ID: 2463852
    [Abstract] [Full Text] [Related]

  • 32. Erythrocyte calcium abnormalities and the clinical severity of sickling disorders.
    Steinberg MH, Eaton JW, Berger E, Coleman MB, Oelshlegel FJ.
    Br J Haematol; 1978 Dec 09; 40(4):533-39. PubMed ID: 728370
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Partially oxygenated sickled cells: sickle-shaped red cells found in circulating blood of patients with sickle cell disease.
    Asakura T, Mattiello JA, Obata K, Asakura K, Reilly MP, Tomassini N, Schwartz E, Ohene-Frempong K.
    Proc Natl Acad Sci U S A; 1994 Dec 20; 91(26):12589-93. PubMed ID: 7809083
    [Abstract] [Full Text] [Related]

  • 39. Hemolysis in sickle cell disease.
    Bensinger TA, Gillette PN.
    Arch Intern Med; 1974 Apr 20; 133(4):624-31. PubMed ID: 4594397
    [No Abstract] [Full Text] [Related]

  • 40. Inhibition of the in vitro formation of irreversibly sickled cells by cepharanthine.
    Ohnishi ST.
    Br J Haematol; 1983 Dec 20; 55(4):665-71. PubMed ID: 6671086
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.